DHT helps explain why the prostate often grows with age and why saw palmetto appears in so many men’s health formulas. This guide explains the pathway in clear, practical language.
By Dr. Marcus Reed, MD · Last Updated: July 23, 2026
DHT, or dihydrotestosterone, is a potent androgen created when the enzyme 5-alpha-reductase converts testosterone. In prostate tissue, DHT binds strongly to androgen receptors and contributes to the cell growth associated with benign prostatic hyperplasia. Prescription 5-ARI medicines target this enzyme, while ingredients such as saw palmetto and beta-sitosterol are studied for activity along the same pathway.
Understanding DHT makes the biology of prostate enlargement easier to follow. It helps explain why symptoms become more common with age, why testosterone levels alone do not predict BPH, why the same pathway is linked with male-pattern hair loss, and why saw palmetto leads so many prostate formulas. The sections below explain the mechanism and the available ways to address it.
Testosterone is the headline male hormone, but in several tissues it functions largely as a precursor. The enzyme 5-alpha-reductase converts testosterone into dihydrotestosterone, and DHT binds the androgen receptor with roughly five times the affinity and dissociates from it much more slowly. In practical terms, DHT is the more powerful signal.
There are two main isoforms of the enzyme. Type 1 is found mostly in skin and liver; type 2 dominates in the prostate, seminal vesicles, and hair follicles. This tissue distribution is why DHT is simultaneously the driver of prostate growth and male pattern baldness—the same hormone, different tissues, different visible consequences.
Only about 5% of circulating testosterone is converted to DHT systemically. But inside the prostate, local conversion is far higher, and DHT concentrations in prostate tissue substantially exceed testosterone concentrations. This is the key point: prostate growth is governed by what happens locally inside the gland, not by your blood testosterone number.
Within prostate cells, DHT binds the androgen receptor, the complex moves to the nucleus, and it switches on genes that promote cell proliferation and suppress programmed cell death. Over decades, more cells are produced than removed, and the gland grows. This is hyperplasia—an increase in cell number—which is why the condition is called benign prostatic hyperplasia rather than hypertrophy.
Two observations confirm the mechanism convincingly. Men who lack functional 5-alpha-reductase type 2 due to a rare genetic condition have small prostates and do not develop BPH. And men castrated before puberty do not develop it either. The androgen signal is necessary for the process.
There is a second layer worth knowing. As men age, the balance between androgens and estrogens shifts, and estrogen appears to sensitise prostate tissue to DHT's growth signal. This helps explain the timing—why prostates grow throughout adulthood but symptoms typically emerge in the fifties and sixties, when the hormonal ratio has drifted.
Men often notice the overlap and wonder if it is coincidence. It is not. DHT causes prostate cells to proliferate and, in genetically susceptible scalp follicles, causes the opposite—follicular miniaturisation, producing progressively finer hairs until the follicle stops producing visible hair altogether. Same hormone, opposite tissue response.
This is also why finasteride, a 5-alpha-reductase inhibitor, is prescribed at 5mg for BPH and 1mg for male pattern hair loss. One drug, one enzyme, two indications. It is a useful mental shortcut: anything that meaningfully lowers DHT tends to affect both the prostate and the hairline.
Prescription 5-ARIs—finasteride and dutasteride—block the enzyme directly. Finasteride primarily inhibits type 2; dutasteride inhibits both isoforms and lowers serum DHT more completely. Over six to twelve months these drugs can reduce prostate volume by roughly 20-25% and improve symptom scores.
They are effective but not consequence-free. Reported side effects include reduced libido, erectile difficulty, and ejaculatory changes in a minority of men, and a small proportion report persistent effects. They also lower PSA by roughly half, which must be accounted for when interpreting screening results. And they are slow—unlike alpha-blockers, which relieve symptoms within days by relaxing smooth muscle, 5-ARIs work by shrinking tissue and take months.
None of this is an argument against them. For men with clearly enlarged prostates and significant symptoms they are a well-evidenced option. It is an argument for having the conversation with a doctor who can weigh your specific situation.
The pharmacological logic—inhibit the enzyme, reduce the growth signal—is exactly what natural prostate ingredients attempt at a gentler magnitude.
The most-studied botanical in this space. Laboratory work indicates saw palmetto's fatty acid and sterol fraction can inhibit both isoforms of 5-alpha-reductase, and it also appears to interfere with DHT binding to androgen receptors in prostate tissue. Clinical results have been mixed across trials—which is largely a story about extract quality, since only liposterolic extracts standardized for fatty acid content resemble what was used in the positive studies. A randomized trial of a natural-product combination including saw palmetto reported significantly reduced nocturia and frequency (PMID 12092634).
The primary plant sterol in saw palmetto and many other plants. It has been shown to inhibit 5-alpha-reductase, behaving in the same direction as finasteride though far more weakly, and has its own body of BPH evidence (PMID 38148931). A phytosterol-enriched saw palmetto oil outperformed conventional saw palmetto oil in a randomized placebo-controlled trial, with significant improvements in symptom scores and urine flow (PMID 32620155).
Works less through the enzyme and more through anti-inflammatory and growth-factor pathways, which makes it complementary rather than redundant alongside saw palmetto. Meta-analysis found it reduced nocturia and improved urine flow versus placebo (PMID 11099686).
Zinc is concentrated in prostate tissue and has been examined for a role in 5-alpha-reductase activity, though the evidence here is much weaker than for the botanicals. It is better understood as supporting normal prostate function than as a DHT blocker.
Multi-ingredient formulas such as ProstaStream combine saw palmetto, beta-sitosterol, and pygeum precisely because they hit different points in the same problem. A fair way to frame it: these are mild modulators, not pharmaceutical-grade enzyme blockers. Expect gradual symptom support in mild-to-moderate cases, not the 20% volume reduction a prescription 5-ARI can achieve.
Two misreadings are common and worth correcting.
First, lowering DHT is not automatically good. DHT is a normal, necessary hormone with roles in libido, erectile function, and muscle. The goal in BPH is not eliminating it but moderating an excessive local growth signal in one tissue. Men sometimes take stacks of DHT-blocking supplements hoping for benefit and end up with sexual side effects instead.
Second, testosterone therapy and prostate risk are more nuanced than the old dogma. The long-standing assumption that raising testosterone raises prostate risk has been substantially revised in recent years, though it remains an area where you should follow a doctor's guidance rather than internet consensus. If you are on or considering TRT and have urinary symptoms, that is a conversation for a urologist.
For most men with urinary symptoms, the answer is no—and understanding why is helpful.
Serum DHT can be measured, but it tells you relatively little about what is happening inside the prostate. As covered above, prostate growth is governed by local intraprostatic conversion, and tissue DHT concentrations do not track neatly with blood levels. Two men with identical serum DHT can have very different prostate volumes, because the enzyme activity and receptor sensitivity inside the gland differ.
This is why urologists assess the prostate directly—symptom scores, physical examination, urine flow measurement, post-void residual volume, and imaging where indicated—rather than ordering hormone panels. The functional question is how much the gland is obstructing flow, not what a hormone number reads.
There are exceptions. DHT and broader androgen testing has a place in investigating specific conditions such as suspected androgen deficiency, certain developmental disorders, or when monitoring particular therapies. But ordering a DHT test to work out whether your prostate is a problem is answering the wrong question with an expensive test.
Translating the biology into decisions:
The overall picture is reassuring rather than alarming. Prostate enlargement is a slow, well-understood, hormonally-driven process with a clear mechanism and a graded set of options. Knowing that DHT sits at the center of it makes every option on the ladder—from a tomato-rich diet to a saw palmetto capsule to a prescription—easier to evaluate on its merits.
Key takeaway: DHT, converted from testosterone by 5-alpha-reductase, is the growth signal behind prostate enlargement. Prescription 5-ARIs block that enzyme strongly; saw palmetto and beta-sitosterol nudge the same pathway gently. Understand it as a signal to moderate, not a hormone to eliminate.
A 15-ingredient prostate formula built around saw palmetto, beta-sitosterol, and pygeum, backed by a 60-day money-back guarantee.
Order from Official Website